EE9900528A - CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks - Google Patents

CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks

Info

Publication number
EE9900528A
EE9900528A EEP199900528A EEP9900528A EE9900528A EE 9900528 A EE9900528 A EE 9900528A EE P199900528 A EEP199900528 A EE P199900528A EE P9900528 A EEP9900528 A EE P9900528A EE 9900528 A EE9900528 A EE 9900528A
Authority
EE
Estonia
Prior art keywords
disruptor
binding
immune responses
graft rejection
adaptive immune
Prior art date
Application number
EEP199900528A
Other languages
English (en)
Inventor
D. Kirk Allan
M. Harlan David
W. Thomas David
Kauffman Michael
Burkly Linda
Original Assignee
Biogen, Incorporated
The United States Of America As Represented By The Secretary Of The Navy Chief Ofnaval Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated, The United States Of America As Represented By The Secretary Of The Navy Chief Ofnaval Research filed Critical Biogen, Incorporated
Publication of EE9900528A publication Critical patent/EE9900528A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
EEP199900528A 1997-05-17 1998-05-15 CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks EE9900528A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4679197P 1997-05-17 1997-05-17
US4938997P 1997-06-11 1997-06-11
US8514598P 1998-05-12 1998-05-12
PCT/US1998/010075 WO1998052606A1 (en) 1997-05-17 1998-05-15 Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection

Publications (1)

Publication Number Publication Date
EE9900528A true EE9900528A (et) 2000-06-15

Family

ID=27366975

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900528A EE9900528A (et) 1997-05-17 1998-05-15 CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks

Country Status (20)

Country Link
US (2) US20020119150A1 (et)
EP (1) EP0980259A1 (et)
JP (1) JP2002500648A (et)
KR (1) KR100575069B1 (et)
CN (1) CN1202864C (et)
AU (1) AU735592B2 (et)
BG (1) BG64841B1 (et)
BR (1) BR9809641A (et)
CA (1) CA2291156A1 (et)
EA (1) EA002549B1 (et)
EE (1) EE9900528A (et)
HU (1) HUP0003392A3 (et)
IL (1) IL132882A0 (et)
IS (1) IS5247A (et)
NO (1) NO995617L (et)
NZ (1) NZ500974A (et)
PL (1) PL192521B1 (et)
SK (1) SK156099A3 (et)
TR (1) TR199902817T2 (et)
WO (1) WO1998052606A1 (et)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768547B2 (en) * 1999-01-08 2003-12-18 Wisconsin Alumni Research Foundation Methods of prolonging transplant survival using immunotoxins and costimulation blockade of CD154 and CD28
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP2003512439A (ja) * 1999-10-22 2003-04-02 バイオジェン インコーポレイテッド 眼の免疫学的合併症を処置するためのｃｄ４０：ｃｄ１５４結合遮断剤の使用
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CN1438894A (zh) * 2000-06-09 2003-08-27 布里斯托尔-迈尔斯斯奎布公司 通过阻断淋巴细胞信号和阻断lfa－1介导的粘附作用调节细胞介导的免疫应答的方法
EP1179587A1 (de) * 2000-08-09 2002-02-13 Genethor GmbH Verfahren zur Reduzierung von spezifischen Immunreaktionen
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
NZ544486A (en) * 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CN101072587B (zh) 2004-07-26 2012-12-26 比奥根艾迪克Ma公司 抗-cd154抗体
JP5014143B2 (ja) * 2005-10-14 2012-08-29 学校法人福岡大学 膵島移植における移植膵島障害抑制剤
AR058135A1 (es) * 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1968386A4 (en) * 2005-12-15 2009-07-22 Univ New York State Res Found METHOD FOR TREATING UNDERFUNCTION OF THE IMMUNE SYSTEM BY REGULATING THE CD40 LIGAND EXPRESSION
US8771686B2 (en) * 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
JP5754875B2 (ja) * 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
TWI438208B (zh) * 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
CN104906581A (zh) * 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
EP3229586A4 (en) 2014-12-10 2018-10-24 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
MX2018001522A (es) 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
CN117843789A (zh) 2017-05-24 2024-04-09 Als治疗发展学会 治疗性抗cd40配体抗体
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201095B (en) * 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ES2112431T3 (es) * 1992-08-21 1998-04-01 Genentech Inc Procedimiento para el tratamiento de un trastorno mediado por lfa-1.
JPH06298654A (ja) * 1993-04-12 1994-10-25 Sumitomo Electric Ind Ltd 抗原特異的免疫抑制剤
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
JP2001508450A (ja) * 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物の治療学的投与の方法

Also Published As

Publication number Publication date
PL336994A1 (en) 2000-07-31
WO1998052606A1 (en) 1998-11-26
KR100575069B1 (ko) 2006-05-02
BG64841B1 (bg) 2006-06-30
US20070244053A1 (en) 2007-10-18
CN1202864C (zh) 2005-05-25
AU735592B2 (en) 2001-07-12
PL192521B1 (pl) 2006-11-30
SK156099A3 (en) 2000-06-12
CN1261284A (zh) 2000-07-26
JP2002500648A (ja) 2002-01-08
EP0980259A1 (en) 2000-02-23
NZ500974A (en) 2001-06-29
IS5247A (is) 1999-11-12
EA002549B1 (ru) 2002-06-27
IL132882A0 (en) 2001-03-19
AU7494098A (en) 1998-12-11
KR20010012671A (ko) 2001-02-26
NO995617L (no) 2000-01-17
BG103948A (en) 2000-07-31
CA2291156A1 (en) 1998-11-26
US20020119150A1 (en) 2002-08-29
HUP0003392A2 (hu) 2001-08-28
NO995617D0 (no) 1999-11-16
HUP0003392A3 (en) 2002-09-30
EA199901046A1 (ru) 2000-10-30
BR9809641A (pt) 2000-07-11
TR199902817T2 (xx) 2000-09-21

Similar Documents

Publication Publication Date Title
EE9900528A (et) CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks
HUP0402247A3 (en) Antibodies to cd40
FI971060A (fi) Mukautuva suodatin
WO2002028904A3 (en) Human anti-cd40 antibodies
HUP1500179A2 (en) The use of human tnf-alpha binding antibodies
AU2002210299A1 (en) Adaptive personal repeater
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
DK0906784T3 (da) Fremgangsmåde til fremstilling af bundne zeolitter
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
DE19581637T1 (de) Multifunktionelle, biologisch dispergierende/biozide Zusammensetzungen
AU2001280934A1 (en) Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
HUP0200912A2 (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction
DK0694706T3 (da) Adaptiv glidekobling
DE19882141T1 (de) Adaptive Doppelfilter-Echolöschung
HUP9902111A3 (en) Bicyclic amines and their n-oxides, intermediates, preparation and use thereof, insecticide, acaricide and nematocide compositions containing these compounds
DE69634466D1 (de) Mehrbenutzerempfang für CDMA
DK1025253T3 (da) Positiv-negativ-selektion ved den homologe rekombination
PL337331A1 (en) Cyanoguanidines as cell proliferation inhibitors
EE9900551A (et) Tsüanoguanidiinid kui rakkude paljunemise inhibiitorid
MXPA02009449A (es) Ligandos dirigidos a la region no del eje del componente no secretor de la pigr y metodos de uso de los mismos.
AU3179999A (en) Methods to treat undesirable immune responses
EP1366056A4 (en) PREPARATION OF DEOXYNUCLEOSIDES
AU2003285483A1 (en) Conjugate composition comprising antibodies against cd40 or cd28
GB9915108D0 (en) Zeolite filter
EP1354601A4 (en) INHIBITORS OF RELEASE OF TRANSPLANT ORGANS

Legal Events

Date Code Title Description
HC1A Change of owner name